A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Early biologic response patterns in plaque psoriasis revealed faster remission with anti-IL-17AF and underscored the need for tailored treatment strategies.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

A new consensus statement endorsed by the National Psoriasis Foundation formally defined on-treatment remission for plaque psoriasis, an effort to improve the ability of clinicians and ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

The autoimmune disease causes raised, scaly patches of skin. As a child, it left the football star embarrassed to remove his shirt at the pool. But he has found ways to manage it.